Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Juvenile Arthritis Data For Novartis' Ilaris Also Supports Role In Gouty Arthritis

This article was originally published in The Pink Sheet Daily

Executive Summary

Novartis' canakinumab shows promise in the first of two Phase III studies in systemic juvenile idiopathic arthritis, a severe and apparently distinct form of juvenile arthritis.

You may also be interested in...



Novartis Takes Stock Of Ilaris For Gout Following FDA's Complete Response Letter

The agency seeks more clinical data on canakinumab in refractory patients after an advisory committee meeting that focused on the drug's potential risks.

Ilaris Safety Data Inadequate For Gout Indication, FDA Panel Says

Arthritis Advisory Committee votes against approval of Novartis' biologic for treatment of gout attacks, citing the need for more data on long-term safety and retreatment, along with a narrower indication.

NIBR Model Improves Novartis Early Pipeline Success Rate

Eight years after Novartis AG launched the Novartis Institutes for Biomedical Research under Harvard Medical School cardiologist Mark Fishman and let him design a novel strategy for vetting early-stage projects, the company's Phase II success rate for new molecular entities has doubled.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS072787

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel